There are 2789 resources available
59TiP - Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
Presenter: Jennifer Knox
Session: ePoster Display
62P - Markers in assessment of osteoporosis therapy efficiency in hormone-dependent breast cancer
Presenter: Nailya Guskova
Session: ePoster Display
95P - Optimizing selection of experimental treatment for patients with advanced cancer using whole genome sequencing
Presenter: Melinda Pruis
Session: ePoster Display
66P - Leptin receptor (Ob-R) and its association with tumour infiltrating lymphocytes (TILs) in early breast cancer (BC): Correlation with pathological complete response (pCR)
Presenter: Laura García Estevez
Session: ePoster Display
35P - The effect of smoking on the immune microenvironment and immunogenicity and its relationship with the prognosis of immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Yueqin Sun
Session: ePoster Display
161P - Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Presenter: David Veenstra
Session: ePoster Display
162P - Prevalence and spectrum analysis of germline BRCA1 and BRCA2 variants of unclear significance in HBOC Syndrome: Decoding the mysterious signals of the genome
Presenter: Alessia Fiorino
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display